Breaking Finance News

Shore Capital retained GlaxoSmithKline PLC (LON:GSK) to Hold in a statement released earlier today.

Shore Capital has retained GlaxoSmithKline PLC (LON:GSK) to Hold in a report released on 4/21/2017.

Previously on Thursday April 20, 2017, Jefferies International released a statement about GlaxoSmithKline PLC (LON:GSK) reduced the target price from 1,850.00GBX to 1,800.00GBX. At the time, this indicated a possible upside of 0.14%.

Just yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.22% higher at 1,561.75GBX. GlaxoSmithKline PLC’s 50-day moving average is 1,660.68GBX and its 200-day moving average is 1,595.67GBX. The last stock price is down -1.86% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Volume of trade was down over the average, with 1,517,297 shares of GSK changing hands under the typical 8,506,160

Performance Chart

GlaxoSmithKline PLC (LON:GSK)

With a total market value of 0 GBX, GlaxoSmithKline PLC has price-earnings ratio of 84.19 with a one year low of 1,363.00GBX and a one year high of 1,745.56GBX .

A total of 24 analysts have released a research note on GSK. Three analysts rating the company a strong buy, six analysts rating the company a buy, seventeen analysts rating the company a hold, two analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of 1,577.33GBX.

More About GlaxoSmithKline PLC (LON:GSK)

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.